-
Achieved $100.3 million in net sales in 2025, representing 54% year-over-year growth driven by a doubling of the installed base to 35,000 users.
-
He attributed the sales force’s productivity to iLet’s fully automated algorithm and digital ecosystem, allowing a smaller team of 63 territories to compete effectively against larger traditional companies.
-
Successfully executed a pharmacy channel strategy, establishing formulary agreements with leading US PBMs to reduce patients’ out-of-pocket costs and drive high-margin recurring revenue.
-
Maintained the strongest gross margin profile in the durable dispenser space at 55.4%, despite the near-term dilutive effects of rapid pharma channel expansion.
-
Significant market expansion was seen through iLet, with 69% of new patient starts coming from people who were previously using multiple daily injections rather than switching from other pumps.
-
It reported that 25% to 30% of new patients started in the fourth quarter were off-label type 2 diabetes users, highlighting strong organic demand ahead of a formal regulatory indication.
-
Addressed the January 2026 FDA warning letter, clarifying that the findings related to complaint handling definitions (e.g., reporting self-treated hypoglycemia) and software update submission procedures rather than product safety.
-
Projected 2026 revenue of $130 million to $135 million, assuming stable DME prices and low single-digit price growth for pharmaceutical supplies.
-
It anticipates 2026 gross margins between 55.5% and 57.5%, with sequential quarterly improvements as manufacturing leverage and pharmacy recurring revenue scale.
-
Plans to expand sales force in at least 20 new territories in 2026, focusing on high-quality representatives in priority markets to increase endocrinologist and primary care reach.
-
Q1 2026 revenue is expected to decline sequentially from Q4 2025 due to annual deductible resets and the absence of specific product launch tailwinds seen in early 2025.
-
Committed to an unrestricted commercial launch of the Mint Patch pump by the end of 2027, leveraging existing PBM contracts for rapid coverage.
-
A remediation timeline for the FDA warning letter was confirmed, with the goal of bringing all historical complaint submissions into full compliance by the end of the second quarter of 2026.
-
It saw a $1 million advance in stock orders from the first quarter of 2026 to the fourth quarter of 2025, as pharmaceutical channels anticipated price increases by the end of the year.
-
Pharmacy mix volatility was identified as a key risk factor, as rapid shifts towards pharmacy openings create short-term revenue and margin headwinds despite long-term growth.
-
Changed disclosure practices to no longer provide exact quarterly new patient initiation figures, aligning with industry peers and maintaining revenue transparency by channel.